Screener / SEC EDGAR /CIK 0002019410 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Medical Labs

Caris Life Sciences, Inc. CAI

Compare with peers Embed
What it said it expected, against what it reported

1 target with a reported result

Releases of the last 3 years
Above the range 1 above the last range given
Within the range 0 of 1 range targets
Below the range 0 below the last range given

The numbers CAI said it expected, in its earnings releases, next to what it then reported for the same period.

Target by target

Each target, with the sentence it came from · release and 10-Q or 10-K

The last range givenReported, abovewithin or keptbelow or missed
TargetWhat the company saidReportedResult
Revenue
Fiscal 2026
Given $1.00B to $1.02B release Feb 26, 2026
Kept $1.00B to $1.02B release May 7, 2026
Raised $1.03B to $1.04B release Aug 5, 2026
Raised $1.04B to $1.05B release Nov 4, 2026
– Not reported yet
The company's words
Expects full year 2026 revenue to be in the range of $1.0 billion to $1.02 billion release Feb 26, 2026
Caris Life Sciences reaffirms its guidance for full year 2026 revenue to be in the range of $1.0 billion to $1.02 billion, representing growth of 23% to 26% compared to full year 2025 and reaffirms its guidance to clinical therapy selection volume growth of approximately 20% compared to full year 2025. release May 7, 2026
Raises 2026 revenue guidance to $1.03 to $1.04 billion, representing growth of 27% to 28% release Aug 5, 2026
Raises 2026 revenue guidance to $1.04 to $1.05 billion, representing growth of 28% to 29% release Nov 4, 2026
Revenue
Fiscal 2025 (ended Dec 31, 2025)
Given $675.00M to $685.00M release Aug 12, 2025
Raised $720.00M to $730.00M release Nov 5, 2025
$812.03M
10-K filed 2026-03-03
Above the range
The company's words
Caris Life Sciences expects full year 2025 revenue to be in the range of $675.0 million to $685.0 million, representing growth of 64% to 66% compared to full year 2024. release Aug 12, 2025
Raises 2025 revenue guidance to $720 to $730 million, representing year-over- year growth of 75-77% release Nov 5, 2025

Targets are read from the sentences of the EX-99 exhibits of 8-K item 2.02 filings (7 releases since 2025-08-12), without AI; in outlook tables only the first column is read. The result compares the reported number with the last range given before the period was reported. Results come from SEC's XBRL company facts, as first reported. A company's target can use its own definition (META's capital expenditures include finance lease payments, for example), so read the quote.

Sources

The outlook sentences of each earnings release (8-K item 2.02, exhibit 99), read without AI; results from SEC's XBRL company facts, as first reported.

Also

Earnings releases: each release in full.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/CAI/export.csv") into a cell.

Next:Archive
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.